Inflammatory Bowel Disease (IBD)


TARGET-IBD continues to collect valuable real-world data which enhances our understanding of the natural history of inflammatory bowel disease and the impact of different treatment paradigms on patient populations over time. The outcomes from real-world evidence can help doctors as they work to provide treatments to individual patients in real-life settings. This is particularly important given the ongoing innovation in the treatment of IBD. Millie Long, MD, MPH

According to the Centers for Disease Control and Prevention, it was estimated that a total of 1.3% or 3 million adults in the U.S. reported being diagnosed with inflammatory bowel disease in 2015 alone. This increasing number of millions of diagnosed individuals is evident that there is a true need for real-world, longitudinal data evaluating the disease to find new understandings.

TARGET produces meticulously curated, real-world patient data by sponsoring longitudinal observational studies in specific diseases through a network of both academic and community-based sites and principal investigators.

The TARGET-IBD study aims to uncover these findings by collecting various sets of consented, real-world patient data from medical records, patient reported outcomes, and biospecimens. This data is critical in establishing real-world evidence findings of the IBD disease, as robust pipelines of new chemical entities and bio-similar entrants continues to have profound effects on patient management. 

study goals:

  • Expand enrollment of the TARGET-IBD cohort with rapid acquisition of detailed clinical data from academic and community practice settings
  • Explore the safety and effectiveness of the entire spectrum of current and future therapies, including the occurrence of switching to bio-similars, that are utilized in usual clinical practice across diverse populations


August 2017


enrollment goal:

Up to 15,000


Looking for a custom RWE solution? With our broad and extensive real-world database encompassing a multitude of diseases, TARGET has proven experience in providing easier, more feasible ways to generate and analyze patient data in real settings. Let us work with you to create a complete data solution built specifically for your RWE needs. 

TARGET-IBD Steering Committee

Bruce Sands, MD (Co-Chair)
Dr. Burrill B. Crohn Professor of Medicine, New York, NY

Millie D. Long, MD, MPH (Co-Chair)
Associate Professor of Medicine, Chapel Hill, NC

David Rubin, MD (Co-Chair)
Joseph B. Kirsner Professor of Medicine, Chicago, IL

Marla Dubinsky, MD
Chief of the Division of Pediatric Gastroenterology and Professor of Medicine, New York, NY

John Hanson, MD
Gastroenterology Specialist, Charlotte, NC

Miguel Regueiro, MD
Professor and Chairman of Gastroenterology and Hepatology, Cleveland, OH